IFNG and neoplasm: More interestingly, CTLA‐4 inhibitor (ipilimumab) therapy leads to an increase in an IFNG‐response gene expression signature in melanoma patients, including CTLA‐4 itself.43 However, there is an urgent need to investigate the function of CTLA‐4 on melanoma cells in tumor immune escape.